Thanks to biotechnology, immunotherapy has become standard of care along many a cancer patient's journey, with many targeted drugs now available. One of the oldest and most successful immunotherapies is simpler: a tamed version of a classic vaccine, against the infectious disease tuberculosis (TB).
"BCG" is the "treatment" vaccine's technical name, for Mycobacterium bovis Bacillus Calmette-Guérin. Oncologists have used BCG to treat early stage bladder cancer for decades.
A research team led by Rita Fior at the Champalimaud Centre for the Unknown, Lisbon, Portugal, figured out how BCG decimates cancer cells. Their report appears in Disease Models and Mechanisms. First author is Mayra Martínez-López, who was a PhD student at the lab and is now at the Universidad de las Américas in Quito, Ecuador.
Immunotherapy Began with Coley's Toxins
Retooling vaccines to kill cancer cells is a classic tale in the history of medicine.